Antares Pharma Stock Soars After $960 Million Halozyme Buyout
Text size
Nasdaq-listed Antares Pharma is being bought by Halozyme Therapeutics in a deal valued at $960 million.…
SoulMete - Informative Stories from Heart. Read the informative collection of real stories about Lifestyle, Business, Technology, Fashion, and Health.